Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pre-emption Rule Delays Safety-related Label Changes, Waxman Charges

Executive Summary

An FDA rule that requires the agency to approve labeling changes before they can be made has delayed the addition of safety information to at least two products, according to a report from Rep. Henry Waxman, D-Calif

You may also be interested in...



OTC Decisions In April: Naproxen CV Risk Warning, Sun US Line Rises, Perrigo Omeprazole 'Melt In Mouth' Flag

The first US approvals for adding cardiovascular risk warnings to OTC naproxenb products were for the Aleve line of multiple formulations and delivery formats and in multiple container sizes and Biopharma and Catalent 220-mg capsules. Sun Pharma extends into expectorant/allergy and diarrhea remedy spaces in US OTC market.

Who’s Next In Congressional Hot Seat? Pharma Industry Could Replace FDA

Congress will not keep up its intense scrutiny of FDA when President-elect Barack Obama takes office, drug and device lawyers predict. Instead, Capitol Hill will shift its attention to pharmaceutical company practices

Who’s Next In Congressional Hot Seat? Pharma Industry Could Replace FDA

Congress will not keep up its intense scrutiny of FDA when President-elect Barack Obama takes office, drug and device lawyers predict. Instead, Capitol Hill will shift its attention to pharmaceutical company practices

Related Content

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel